유럽 연합 - 영어 - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart - diabetes mellitus - drugs used in diabetes - novorapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

유럽 연합 - 영어 - EMA (European Medicines Agency)

novo nordisk a/s - eptacog alfa (activated) - hemophilia b; thrombasthenia; factor vii deficiency; hemophilia a - antihemorrhagics - novoseven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bethesda units (bu);in patients with congenital haemophilia who are expected to have a high anamnestic response to factor-viii or factor-ix administration;in patients with acquired haemophilia;in patients with congenital factor-vii deficiency;in patients with glanzmann's thrombasthenia with antibodies to platelet glycoprotein (gp) iib-iiia and / or human leucocyte antigens (hla), and with past or present refractoriness to platelet transfusions.in patients with glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available. 

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - insulin aspart 100 u/ml;   - solution for injection - 100 u/ml - active: insulin aspart 100 u/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol sodium chloride sodium hydroxide water for injection zinc - treatment of diabetes mellitus

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin detemir, quantity: 100 u/ml - injection, solution - excipient ingredients: glycerol; sodium hydroxide; dibasic sodium phosphate dihydrate; water for injections; hydrochloric acid; zinc acetate; metacresol; phenol; sodium chloride - treatment of diabetes mellitus. (see 'pharmacology' and 'clinical trials.')

싱가포르 - 영어 - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - repaglinide - tablet - 0.5mg/tablet - repaglinide 0.5 mg

싱가포르 - 영어 - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - repaglinide - tablet - 1mg/tablet - repaglinide 1mg/tablet

싱가포르 - 영어 - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - repaglinide - tablet - 2mg/tablet - repaglinide 2mg/tablet

유럽 연합 - 영어 - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa - hemophilia a - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). novoeight can be used for all age groups.

유럽 연합 - 영어 - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart - diabetes mellitus - drugs used in diabetes - treatment of diabetes mellitus.

말레이시아 - 영어 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - eptacog alfa (activated) (recombinant cougulation factor viia); eptacog alfa -